It’s noteworthy that the predictive efficiency of this MRGs-related signature for NB patients surpasses that of MYCN, traditionally recognized as the best genetic marker for forecasting outcomes in NB (52, 53). The gene discussed is MYCN; the disease is neuroblastoma.